Archana Mavoori; Sneha Pamar; Sudha Bala
Abstract
Background: Secukinumab is a fully humanized IL-17A antagonist approved for managing moderate-to-severe plaque psoriasis as well as psoriatic arthritis. This study assessed the speed of action of secukinumab and the improvement in the quality of life in a series of patients.Methods: We aimed to assess ...
Read More
Background: Secukinumab is a fully humanized IL-17A antagonist approved for managing moderate-to-severe plaque psoriasis as well as psoriatic arthritis. This study assessed the speed of action of secukinumab and the improvement in the quality of life in a series of patients.Methods: We aimed to assess changes in the PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life QualityIndex) following a course of secukinumab injections. Methods: This hospital-based study was conducted in the Department of Dermatology, Venereology and Leprosy of ESIC Medical College & Hospital, Hyderabad, India.Results: Starting from 8 weeks after initiation of treatment with secukinumab 300 mg, a clinically significant response was observed, with progressive reduction of skin disease indices. Twenty-four patients were included in the study, with a mean age of 42 years. The male to female ratio was 15:9. Thirteen (54.16%) patients achieved PASI 75 at eight weeks. At the end of 52 weeks, 20 (83.33%), 15 (62.5%), and 8 (33.33%) patients maintained PASI 75, PASI 90, and PASI 100, respectively.Conclusion: Secukinumab is a highly-efficacious, biologic therapy that provides rapid relief with a relatively favorable safety profile in patients with moderate-severe plaque psoriasis. In addition, secukinumab is a preferred treatment for patients with comorbid psoriatic arthritis or arthralgia symptoms due to its ability to arrest the progression of arthritic disease in the early course.
Nitin Joseph; Deepti D’Souza; Matthew Antony Manoj; Shajimon Priya Varsha; Tanya Singh; Archit Gupta; Akshiti Kaushik
Abstract
Background: Psoriasis is an immune-mediated chronic skin disorder. Information regarding its clinic-epidemiological manifestations is limited in parts of Asia. This study was conducted to determine the risk factors, clinical presentation, and management of psoriasis among patients in Mangalore, India. ...
Read More
Background: Psoriasis is an immune-mediated chronic skin disorder. Information regarding its clinic-epidemiological manifestations is limited in parts of Asia. This study was conducted to determine the risk factors, clinical presentation, and management of psoriasis among patients in Mangalore, India. Methods: The medical records of 225 psoriasis patients over the past ten years (from January 2009 till March 2019) were examined by the investigators. Data were collected using a semi-structured form. Results: The mean age at diagnosis of psoriasis was 42.2 ± 16.0 years. Nail psoriasis and psoriatic arthritis (PsA) were present in 66 (29.3%) and 21 (9.3%) patients, respectively. Relapse of psoriasis was seen more among patients with a history of disease exacerbation in winter (P=0.009) or in rainy seasons (P=0.031). Systemic therapy with methotrexate and topical therapy with steroids were used in the management of 52 (23.1%) and 72 (32%) patients, respectively. Phototherapy (n=11) was the most common modality used among the 18 patients with extensive psoriasis. Co-morbidities like diabetes mellitus (P=0.02) and complications like PsA (P=0.008) were associated with greater disease durations among the patients. Conclusion: The proportion of patients with extensive psoriasis was high in the current setting probably because of delayed diagnosis. Awareness about the disease and its clinical manifestations might help in its early identification. Seasonal exacerbation was an important risk factor for psoriasis and it was associated with its relapse. The most common management modalities were topical steroids for psoriasis and phototherapy for extensive psoriasis.
